A Discussion About a Hematology Career in Industry With Drs. Benjamin Kim and Mark Chao
Dr. Benjamin Kim and Dr. Mark Chao discuss what it's like for a hematologist holding an industry position.
Predicting Responses to Gemtuzumab Ozogamicin
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Dr. Raetz looks at a study that shows response-based therapy in both children and adults with ETP-ALL is effective.
Dr. Raetz discusses a report that provides important new insight into improving the accuracy of induction response assessment by incorporating MRD.
Dr. Raetz looks at a report that shows that Ph-like ALL is common across the age spectrum.
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Raetz reviews changes that have emerged in 2016 in the treatment of acute lymphocytic leukemia for both children and adults.
Dr. Raetz looks at a highly promising new monoclonal antibody therapy for CD22-positive B-cell acute lymphoblastic leukemia.
Dr. Raetz looks at the possibility of therapy reduction in carefully defined good risk subsets due to improvements in acute lymphoblastic leukemia outcomes.
Dr. Raetz compares dexamethasone and prednisone for the induction phase of treatment of childhood acute lymphocytic leukemia.
Dr. Raetz and Dr. Loh cover a new study in pediatric ALL that tests the contribution of ruxolitinib to traditional chemotherapy for newly diagnosed, genetically defined subsets of patients who are known to have poor outcomes with standard therapy.
November-December 2017Volume 14, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology